Qiagen has received emergency use authorization (EUA) from the US Food and Drug Administration (FDA) for its QIAstat-Dx Respiratory SARS-CoV-2 Panel test to diagnose patients infected with coronavirus (Covid-19).

The newly developed test kit is the first and only syndromic solution integrating detection of SARS-CoV-2 coronavirus.

QIAstat-Dx test kit can differentiate SARS-CoV-2 from 20 other serious respiratory infections in patients and is capable of delivering results in about one hour.